Victory Pharma acquisition to boost Shionogi's pain ambitions
This article was originally published in Scrip
The Shionogi group company Sciele Pharma is to acquire the private US firm Victory Pharma for $150 million to expand its presence in the pain management area. The deal is expected to close in the second quarter, subject to antitrust and other clearances.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.